NXTC Insiders, Including John Houston, Buy Shares

On June 18, 2026, John Houston, along with several other insiders, bought shares of NXTC. Each insider purchased 2,340 shares, with the transactions not being part of a planned trading program. This insider buying suggests a positive outlook on the company's future.

Other Institutional Activity in NXTC

In the world of institutional investors, Squadron Capital Management LLC increased its stake in NXTC by 28,034 shares, bringing its total to 265,000 shares valued at approximately $2.83 million. Affinity Asset Advisors, LLC, on the other hand, trimmed its holdings by 5,468 shares, now holding 241,826 shares worth about $2.58 million. Ikarian Capital, LLC and Sofinnova Investments, Inc. maintained their positions with 238,303 and 222,654 shares, respectively. Meanwhile, Vanguard Capital Management LLC opened a new position in NXTC, acquiring 160,473 shares valued at $1.69 million.

NextCure, Inc. Stock Down 71.3%

Shares of NXTC traded near $1.75 on Tuesday. NXTC currently lacks a meaningful P/E ratio as it is not profitable. The stock has a market cap of $88.3 million and a beta of 1.2, indicating moderate volatility. Over the past year, the stock has seen a low of $1.50 and a high of $3.00, with a 50-day moving average of $1.70 and a 200-day moving average of $2.10.

Insider Buying and Selling at NextCure, Inc.

On June 18, 2026, several NXTC insiders, including Feigal Ellen, Borgman Anne Elizabeth, Jones Elaine, Webster Stephen, and Kabakoff David, alongside John Houston, bought shares in the company. Each insider purchased 2,340 shares, except for David Kabakoff, who bought 3,510 shares. These transactions were not part of any 10b5-1 trading plans.

Analysts Set New Price Targets

Analysts have been active in setting new price targets for NXTC. On May 11, 2026, Lucid Capital Markets initiated coverage with a buy rating and a $25 price target. Ladenburg Thalmann upgraded the stock to a buy on November 7, 2025, with an $18 target. Piper Sandler and HC Wainwright & Co. have maintained buy ratings with targets of $15 and $3, respectively. The consensus among analysts is a buy recommendation, with an average target price reflecting positive expectations.

About NXTC

NXTC is a biotechnology company focused on developing innovative therapies for unmet medical needs. Headquartered in the United States, it employs a team dedicated to advancing its research and development pipeline. Led by a management team with extensive industry experience, NXTC aims to bring new treatments to market that can improve patient outcomes.

Bottom Line

The recent insider buying activity at NXTC, including purchases by John Houston and other company insiders, suggests a positive sentiment towards the company's prospects. Institutional investors are also adjusting their positions, with some increasing their stakes. Analysts remain optimistic, with several firms maintaining or initiating buy ratings and setting new price targets. Investors often track insider and institutional activities for insights, but it's important to remember that such filings and reports are backward-looking and may not reflect the current situation.